Last updated: June 2, 2026
Suppliers for the pharmaceutical drug pairing probenecid and colchicine are concentrated around: (1) API makers for each active ingredient, and (2) finished-dose manufacturers for fixed-dose combination tablets (where marketed) and separately for each component in local markets. Procurement due diligence should focus on GMP site identity, DMF/CEP status, controlled substance status (none for these actives), and regulatory approvals (FDA Orange Book and global equivalents).
Which companies supply the probenecid API used in colchicine-probenecid products?
Probenecid is a small-molecule uricosuric. Global API supply is typically serviced by multiple generic and specialty API manufacturers across India, China, and Europe.
What suppliers provide probenecid API for regulated markets?
Common supplier patterns (often verified via DMFs and commercial catalogs) include:
- European and US specialty API houses (DMF holders and/or ROW CEP route)
- Indian API manufacturers with US DMF/DMF cross-reference histories
- Chinese API manufacturers supplying global generic packagers
How to qualify a probenecid API supplier for combination use?
Key procurement checks for probenecid API:
- Regulatory filing evidence: US DMF or cross-reference support; EU CEP if used as the basis for local dossier
- Particle size and polymorph controls affecting tablet compression and dissolution consistency
- Impurities profile aligned to labeling specifications for uricosuric use
- Traceability and CoA match for batch release into downstream combination tablets
Which companies supply the colchicine API used with probenecid?
Colchicine has a narrower therapeutic window than many gout drugs, which increases supplier scrutiny on purity, alkaloid profile, and residual solvents.
What suppliers provide colchicine API for regulated markets?
Colchicine API supply is usually split across:
- Specialty fermentation and extraction-route suppliers (starting from botanical sources) or
- Synthetic/semisynthetic route suppliers (depending on manufacturer)
How to qualify a colchicine API supplier for regulated combination tablets?
Procurement qualification for colchicine API should prioritize:
- Source and extraction controls (if botanical-derived), including alkaloid profile consistency
- Residual solvents and heavy metal controls aligned to pharmacopeial expectations
- Stability data for storage and shipping conditions
- Consistent assay and impurity limits that support blend uniformity in low-dose formulations
What finished-dose manufacturers supply probenecid-and-colchicine products?
In many jurisdictions, probenecid and colchicine are sold either as a fixed-dose combination (where available) or as separate products used together in gout regimens.
Are there fixed-dose combinations in the US market?
In the US, procurement often shifts to:
- Separate sourcing: colchicine + probenecid packaged independently
- Cross-market sourcing for fixed-dose tablets if a US-approved fixed-dose option is not routinely marketed
What to check for a finished-dose supplier
A finished-dose manufacturer should meet:
- Current GMP compliance at the specific tablet site
- Labeling alignment to dosing regimen (acute gout vs prophylaxis protocols)
- Quality system evidence for low-dose colchicine blending controls
What FDA and Orange Book status matters for supplier selection?
For supplier selection in the US, the practical path is:
- Identify the approved dosage form(s) (brand or generic) on FDA’s Orange Book
- Map the listed applicants and manufacturers
- Then confirm whether the supplier you plan to use is the same applicant/manufacturing site or a qualified alternative via contractual supply and regulatory support
Why Orange Book mapping drives procurement
For combination procurement, the buyer’s risk is not “API availability,” it is:
- ability to supply approved finished-dose configurations
- continuity of commercial manufacturing authorization
- defensibility of regulatory claims in sourcing and labeling disputes
Do probenecid and colchicine face special regulatory or controlled-supplier constraints?
Neither probenecid nor colchicine is typically treated like a controlled substance under pharmacy controlled-drug regimes in the way opioids are. The supplier constraints are usually:
- GMP and quality system readiness
- batch-to-batch impurity control
- data support for DMF/ANDA-style dossier needs if you are supplying generics/authorized generics
How does patent and exclusivity status affect who can supply?
Patent status affects:
- who can market a finished-dose generic combination (if a fixed-dose exists and is protected)
- who can enter via ANDA (for small molecules) and what paragraph IV routes apply
From a procurement standpoint, the most actionable impact is:
- whether supply is limited to certain applicants tied up in litigation/settlement
- whether you can obtain approved-comparable product quickly from multiple sources
Commercial supplier model: what usually works best for sourcing
Best-practice procurement structure
- Dual-source API procurement: one primary and one qualified backup for both probenecid API and colchicine API
- Finished-dose manufacturing flexibility: qualify more than one tablet packager or CMOD (contract manufacturer and packager) if producing combination tablets
- Regulatory alignment: ensure API and finished-dose sites match the dossiers intended for your market entry
What procurement documents should be requested
- GMP certificates for the specific site
- DMF letter of access (if relied upon)
- CoA for multiple recent lots
- Analytical method validation scope (assay and key impurities)
- Stability protocol and real-time/accelerated data summaries for colchicine due to tighter quality expectations
Key Takeaways
- Probenecid and colchicine supply is typically fragmented across API manufacturers and finished-dose packagers rather than one universal supplier for both.
- Supplier selection is driven by regulatory dossier support (DMF/CEP), GMP site identity, and low-dose colchicine controls.
- For combination availability, procurement often becomes fixed-dose sourcing where marketed or separate sourcing where only individual products exist.
- Orange Book mapping (US) and dossier mapping (global) determine whether you are buying from the parties tied to approved marketing authorization.
FAQs
- How do I verify if a supplier’s probenecid API matches DMF specifications?
- What quality controls matter most for colchicine API batch-to-batch consistency?
- Who manufactures colchicine tablets for gout prophylaxis in the US, and how do I map applicants to sites?
- When fixed-dose probenecid-colchicine tablets are unavailable, what procurement pathway supports equivalent gout regimens?
- Do any probenecid or colchicine suppliers require special qualification for shipping, storage, or stability?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. FDA Drug Master File (DMF) information (FDA guidance and public materials where applicable). U.S. Food and Drug Administration. https://www.fda.gov/drugs/guidance-documents-drugs/drug-master-files-dmfs
